The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer.

Two network meta-analyses showed that in this disease setting the addition of immunotherapy to chemotherapy could be superior to the immunotherapy alone in terms of objective response rate and progression-free survival, while a nonsignificant trend towards improved OS was observed. 23 , 24 An ongoing clinical trial, the randomised phase III INSIGNA study ( ClinicalTrials.gov Identifier: NCT03793179 ), is comparing these approaches, without, however, formally looking at prognostic and predictive factors.

also in 5,406 other papers